Skip to main content
Top
Published in: Supportive Care in Cancer 11/2009

01-11-2009 | Original Article

Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols

Authors: Nilza Nelly Fontana Lopes, Hélio Plapler, Maria Cristina Chavantes, Rajesh V. Lalla, Elisabeth Mateus Yoshimura, Maria Teresa Seixas Alves

Published in: Supportive Care in Cancer | Issue 11/2009

Login to get access

Abstract

Goal of work

The aim of this study was to investigate the mechanisms whereby low-intensity laser therapy may affect the severity of oral mucositis.

Materials and methods

A hamster cheek pouch model of oral mucositis was used with all animals receiving intraperitoneal 5-fluorouracil followed by surface irritation. Animals were randomly allocated into three groups and treated with a 35 mW laser, 100 mW laser, or no laser. Clinical severity of mucositis was assessed at four time-points by a blinded examiner. Buccal pouch tissue was harvested from a subgroup of animals in each group at four time-points. This tissue was used for immunohistochemistry for cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), and factor VIII (marker of microvessel density) and the resulting staining was quantified.

Main results

Peak severity of mucositis was reduced in the 35 mW laser group as compared to the 100 mW laser and control groups. This reduced peak clinical severity of mucositis in the 35 mW laser group was accompanied by a significantly lower level of COX-2 staining. The 100 mW laser did not have an effect on the severity of clinical mucositis, but was associated with a decrease in VEGF levels at the later time-points, as compared to the other groups. There was no clear relationship of VEGF levels or microvessel density to clinical mucositis severity.

Conclusion

The tissue response to laser therapy appears to vary by dose. Low-intensity laser therapy appears to reduce the severity of mucositis, at least in part, by reducing COX-2 levels and associated inhibition of the inflammatory response.
Literature
1.
go back to reference Wilkes JD (1998) Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 25(5):538–551PubMed Wilkes JD (1998) Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 25(5):538–551PubMed
2.
go back to reference Lockhart PB, Sonis ST (1981) Alterations in the oral mucosa caused by chemotherapeutic agents. J Dermatol Surg Oncol 7(12):1019–1025PubMed Lockhart PB, Sonis ST (1981) Alterations in the oral mucosa caused by chemotherapeutic agents. J Dermatol Surg Oncol 7(12):1019–1025PubMed
3.
go back to reference Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, Tishler RB, Canty TP, Kudrimoti MK, Vera-Llonch M (2008) Burden of Illness Head and Neck Writing Committee. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113(10):2704–2713CrossRefPubMed Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, Tishler RB, Canty TP, Kudrimoti MK, Vera-Llonch M (2008) Burden of Illness Head and Neck Writing Committee. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113(10):2704–2713CrossRefPubMed
4.
go back to reference Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14(6):505–515CrossRefPubMed Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14(6):505–515CrossRefPubMed
5.
go back to reference Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262CrossRefPubMed Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253–262CrossRefPubMed
6.
go back to reference McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB (1993) Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 20(10):1493–502PubMed McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB (1993) Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 20(10):1493–502PubMed
8.
go back to reference Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin North Am 52(1):61–77CrossRefPubMed Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin North Am 52(1):61–77CrossRefPubMed
9.
go back to reference Lalla RV, Peterson DE (2006) Treatment of mucositis, including new medications. Cancer J 12(5):348–354CrossRefPubMed Lalla RV, Peterson DE (2006) Treatment of mucositis, including new medications. Cancer J 12(5):348–354CrossRefPubMed
11.
go back to reference Barasch A, Peterson DE, Tanzer JM, D’Ambrosio JA, Nuki K, Schubert MM, Franquin JC, Clive J, Tutschka P (1995) Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantion patients. Cancer 76(12):2550–2556CrossRefPubMed Barasch A, Peterson DE, Tanzer JM, D’Ambrosio JA, Nuki K, Schubert MM, Franquin JC, Clive J, Tutschka P (1995) Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantion patients. Cancer 76(12):2550–2556CrossRefPubMed
12.
go back to reference Bensadoun RJ, Franquin JC, CIais G (1999) Low-energy He/Ne laser in the prevention of radiation mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 7:244–252CrossRefPubMed Bensadoun RJ, Franquin JC, CIais G (1999) Low-energy He/Ne laser in the prevention of radiation mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 7:244–252CrossRefPubMed
13.
go back to reference Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C, Franquin JC (1997) Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 38:697–703CrossRefPubMed Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C, Franquin JC (1997) Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 38:697–703CrossRefPubMed
14.
go back to reference Bensadoun RJ, Magné N, Marcy PY, Demard F (2001) Chemotherapy and radiotherapy induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinol Laryngol 258:481–487CrossRef Bensadoun RJ, Magné N, Marcy PY, Demard F (2001) Chemotherapy and radiotherapy induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinol Laryngol 258:481–487CrossRef
15.
go back to reference Arun MG, Sagar MS, Fernandes D (2006) Effect of low level helium-neon (He-Ne) laser therapy in the prevention and treatment of radiation induced mucositis in head and neck cancer patients. Indian J Med Res 124:399–402 Arun MG, Sagar MS, Fernandes D (2006) Effect of low level helium-neon (He-Ne) laser therapy in the prevention and treatment of radiation induced mucositis in head and neck cancer patients. Indian J Med Res 124:399–402
16.
go back to reference Antunes HS, Azevedo AM, Bouzas LFS, Adão CAE, Pinheiro CT, Mayte R, Pinheiro LH, Azevedo R, Matos VD, Rodrigues PC, Small IA, Zangaro RA, Ferreira CG (2007) Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 109(5):2250–2255CrossRefPubMed Antunes HS, Azevedo AM, Bouzas LFS, Adão CAE, Pinheiro CT, Mayte R, Pinheiro LH, Azevedo R, Matos VD, Rodrigues PC, Small IA, Zangaro RA, Ferreira CG (2007) Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 109(5):2250–2255CrossRefPubMed
17.
go back to reference Cruz LB, Ribeiro AS, Rech A, Rosa JGN, Castro Junior CG, Brunetto A (2007) Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy. Pediatr Blood Cancer 48:435–440CrossRefPubMed Cruz LB, Ribeiro AS, Rech A, Rosa JGN, Castro Junior CG, Brunetto A (2007) Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy. Pediatr Blood Cancer 48:435–440CrossRefPubMed
18.
go back to reference Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJJ, Migliorati CA, Lloid CME, Eduardo CP, Walter NF, Marque MM, Hamdi M (2007) A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 15:1145–1154CrossRefPubMed Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJJ, Migliorati CA, Lloid CME, Eduardo CP, Walter NF, Marque MM, Hamdi M (2007) A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 15:1145–1154CrossRefPubMed
19.
go back to reference Jaguar GC, Prado JD, Nishimoto IN, Pinheiro MC, Castro DO Jr, Cruz Perez DE, Alves FA (2007) Low-energy laser therapy for prevention of oral mucositis in hematopoietic stem cell transplantion. Oral Dis 3(6):538–543CrossRef Jaguar GC, Prado JD, Nishimoto IN, Pinheiro MC, Castro DO Jr, Cruz Perez DE, Alves FA (2007) Low-energy laser therapy for prevention of oral mucositis in hematopoietic stem cell transplantion. Oral Dis 3(6):538–543CrossRef
20.
go back to reference Abramoff MMF, Lopes NNF, Almeida-Lopes L, Dib LL, Lee ML, Delboni A, Caran EM, Petrill AS (2008) Low level laser therapy (685 nm) in the prevention and treatment of chemotherapy-induced oral mucositis in young patients. Photomed Laser Surg 26(4):393–400CrossRefPubMed Abramoff MMF, Lopes NNF, Almeida-Lopes L, Dib LL, Lee ML, Delboni A, Caran EM, Petrill AS (2008) Low level laser therapy (685 nm) in the prevention and treatment of chemotherapy-induced oral mucositis in young patients. Photomed Laser Surg 26(4):393–400CrossRefPubMed
21.
go back to reference Keefe DMK, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831CrossRefPubMed Keefe DMK, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831CrossRefPubMed
22.
go back to reference Sonis ST, Tracey C, Shlar G, Jenson J, Florine D, Almeida C (1990) An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 69:437–443CrossRefPubMed Sonis ST, Tracey C, Shlar G, Jenson J, Florine D, Almeida C (1990) An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 69:437–443CrossRefPubMed
23.
go back to reference Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L, Login G, Ymamkawa M, Moses G Bouchard P, Hayes LL, Bedrosian C, Dorner AJ (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373–381CrossRefPubMed Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L, Login G, Ymamkawa M, Moses G Bouchard P, Hayes LL, Bedrosian C, Dorner AJ (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373–381CrossRefPubMed
24.
go back to reference Corazza AV, Jorge J, Kurachi C, Bagnato VS (2007) Photobiomodulation on the angiogenesis of skin wounds in rats using different light sources. Photomed Laser Surg 25(2):102–105CrossRefPubMed Corazza AV, Jorge J, Kurachi C, Bagnato VS (2007) Photobiomodulation on the angiogenesis of skin wounds in rats using different light sources. Photomed Laser Surg 25(2):102–105CrossRefPubMed
26.
go back to reference Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299:125–140PubMed Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299:125–140PubMed
27.
go back to reference Sonis ST (2002) The biologic role for nuclear factor-kappa B in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13(5):380–389CrossRefPubMed Sonis ST (2002) The biologic role for nuclear factor-kappa B in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13(5):380–389CrossRefPubMed
28.
go back to reference Sonis ST, O’Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170–176CrossRefPubMed Sonis ST, O’Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170–176CrossRefPubMed
29.
go back to reference Logan RM, Gibson RJ, Sonis ST, Keefe DMK (2007) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43(4):395–401CrossRefPubMed Logan RM, Gibson RJ, Sonis ST, Keefe DMK (2007) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43(4):395–401CrossRefPubMed
30.
go back to reference Albertini R, Aimbire F, Villaverde AB, Silva Jr JA, Costa MS (2007) COX-2 mRNA expression decreases in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation after low level laser therapy. Inflamm Res 56:228–229CrossRefPubMed Albertini R, Aimbire F, Villaverde AB, Silva Jr JA, Costa MS (2007) COX-2 mRNA expression decreases in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation after low level laser therapy. Inflamm Res 56:228–229CrossRefPubMed
31.
go back to reference Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120CrossRefPubMed Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120CrossRefPubMed
32.
go back to reference Wallace JL (2006) COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Scientific World Journal 6:577–588PubMed Wallace JL (2006) COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Scientific World Journal 6:577–588PubMed
33.
go back to reference Gilroy DW, Colville-Nash PR, Willis D, Paul-Clark MJ, Willoughby DA (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698–701CrossRefPubMed Gilroy DW, Colville-Nash PR, Willis D, Paul-Clark MJ, Willoughby DA (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698–701CrossRefPubMed
34.
go back to reference Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146(5):1029–1039PubMed Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146(5):1029–1039PubMed
35.
go back to reference Zhang WG, Wu CY, Pan WX, Tian L, Xia JL (2004) Low-power helium-neon laser irradiation enhances the expression of VEGF in murine myocardium. Chin Med J 117(10):1476–1480PubMed Zhang WG, Wu CY, Pan WX, Tian L, Xia JL (2004) Low-power helium-neon laser irradiation enhances the expression of VEGF in murine myocardium. Chin Med J 117(10):1476–1480PubMed
36.
go back to reference Kipshidze N, Nikolaychik V, Keelan MH, Shankar LR, Khanna A, Kornowski R, Leon M, Moses J (2005) Low-power helium: neon laser irradiation enhances production of vascular endothelial growth factor and promotes growth of endothelial cells in vitro. Lasers Surg Med 28:355–364CrossRef Kipshidze N, Nikolaychik V, Keelan MH, Shankar LR, Khanna A, Kornowski R, Leon M, Moses J (2005) Low-power helium: neon laser irradiation enhances production of vascular endothelial growth factor and promotes growth of endothelial cells in vitro. Lasers Surg Med 28:355–364CrossRef
Metadata
Title
Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols
Authors
Nilza Nelly Fontana Lopes
Hélio Plapler
Maria Cristina Chavantes
Rajesh V. Lalla
Elisabeth Mateus Yoshimura
Maria Teresa Seixas Alves
Publication date
01-11-2009
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0603-9

Other articles of this Issue 11/2009

Supportive Care in Cancer 11/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine